CN105451769A - 使用贝那利珠单抗增加哮喘患者用力呼气量的方法 - Google Patents

使用贝那利珠单抗增加哮喘患者用力呼气量的方法 Download PDF

Info

Publication number
CN105451769A
CN105451769A CN201480045047.8A CN201480045047A CN105451769A CN 105451769 A CN105451769 A CN 105451769A CN 201480045047 A CN201480045047 A CN 201480045047A CN 105451769 A CN105451769 A CN 105451769A
Authority
CN
China
Prior art keywords
benralizumab
antigen
binding fragment
weeks
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480045047.8A
Other languages
English (en)
Chinese (zh)
Inventor
C·沃德
L·罗斯科斯
王冰
D·雷布尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Priority to CN202010450690.6A priority Critical patent/CN111588849A/zh
Publication of CN105451769A publication Critical patent/CN105451769A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Endocrinology (AREA)
CN201480045047.8A 2013-08-12 2014-08-07 使用贝那利珠单抗增加哮喘患者用力呼气量的方法 Pending CN105451769A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010450690.6A CN111588849A (zh) 2013-08-12 2014-08-07 使用贝那利珠单抗增加哮喘患者用力呼气量的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361864948P 2013-08-12 2013-08-12
US61/864,948 2013-08-12
PCT/US2014/050119 WO2015023507A2 (en) 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010450690.6A Division CN111588849A (zh) 2013-08-12 2014-08-07 使用贝那利珠单抗增加哮喘患者用力呼气量的方法

Publications (1)

Publication Number Publication Date
CN105451769A true CN105451769A (zh) 2016-03-30

Family

ID=52448838

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480045047.8A Pending CN105451769A (zh) 2013-08-12 2014-08-07 使用贝那利珠单抗增加哮喘患者用力呼气量的方法
CN202010450690.6A Pending CN111588849A (zh) 2013-08-12 2014-08-07 使用贝那利珠单抗增加哮喘患者用力呼气量的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010450690.6A Pending CN111588849A (zh) 2013-08-12 2014-08-07 使用贝那利珠单抗增加哮喘患者用力呼气量的方法

Country Status (26)

Country Link
US (1) US9441046B2 (enExample)
EP (5) EP3033104B1 (enExample)
JP (4) JP6746496B2 (enExample)
KR (1) KR102337599B1 (enExample)
CN (2) CN105451769A (enExample)
AU (2) AU2014306959B2 (enExample)
BR (1) BR112016002317A8 (enExample)
CA (1) CA2917603C (enExample)
CY (2) CY1122033T1 (enExample)
DK (2) DK3520811T3 (enExample)
ES (2) ES2866426T3 (enExample)
HK (1) HK1222559A1 (enExample)
HR (2) HRP20190920T1 (enExample)
HU (2) HUE053627T2 (enExample)
LT (2) LT3033104T (enExample)
ME (1) ME03403B (enExample)
MX (2) MX381102B (enExample)
PL (2) PL3520811T3 (enExample)
PT (2) PT3033104T (enExample)
RS (2) RS58711B1 (enExample)
RU (1) RU2703568C2 (enExample)
SG (1) SG11201600483QA (enExample)
SI (2) SI3520811T1 (enExample)
SM (2) SMT201900311T1 (enExample)
TR (1) TR201907907T4 (enExample)
WO (1) WO2015023507A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105611938A (zh) * 2013-10-24 2016-05-25 免疫医疗有限责任公司 稳定的水性抗体配制品
CN114007641A (zh) * 2019-05-16 2022-02-01 阿斯利康(瑞典)有限公司 使用贝那利珠单抗治疗增强型患者群体慢性阻塞性肺病的方法
CN114423456A (zh) * 2019-09-27 2022-04-29 阿斯利康(瑞典)有限公司 贝那利珠单抗用于治疗迟发性哮喘的方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2918105C (en) * 2013-08-12 2023-02-28 Medimmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
BR112016002462A8 (pt) * 2013-08-12 2018-06-12 Medimmune Llc Métodos para melhorar os sintomas da asma usando benralizumabe
SG10201807318RA (en) * 2013-10-15 2018-09-27 Astrazeneca Ab Methods for treating chronic obstructive pulmonary disease using benralizumab
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法
WO2026053166A1 (en) * 2024-09-06 2026-03-12 Medimmune Limited Anti-il5r-alpha treatment for acute exacerbations of asthma and copd

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066780A2 (en) * 2011-11-01 2013-05-10 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
WO2001060405A1 (en) 2000-02-15 2001-08-23 Kyowa Hakko Kogyo Co., Ltd. Eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
AU2004279740A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Antibody composition specifically binding to IL-5 receptor
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
PT3072525T (pt) * 2007-05-14 2018-04-20 Astrazeneca Ab Métodos para reduzir os níveis de basófilos
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
KR101615420B1 (ko) * 2010-12-16 2016-04-26 제넨테크, 인크. Th2 억제에 관한 진단 및 치료
CN102544908B (zh) 2010-12-17 2016-01-06 富士康(昆山)电脑接插件有限公司 电连接器组件及插头连接器
WO2012158954A1 (en) 2011-05-18 2012-11-22 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
CA2918105C (en) * 2013-08-12 2023-02-28 Medimmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
BR112016002462A8 (pt) * 2013-08-12 2018-06-12 Medimmune Llc Métodos para melhorar os sintomas da asma usando benralizumabe

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066780A2 (en) * 2011-11-01 2013-05-10 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105611938A (zh) * 2013-10-24 2016-05-25 免疫医疗有限责任公司 稳定的水性抗体配制品
CN112107538A (zh) * 2013-10-24 2020-12-22 阿斯利康(瑞典)有限公司 稳定的水性抗体配制品
CN105611938B (zh) * 2013-10-24 2024-12-31 阿斯利康(瑞典)有限公司 稳定的水性抗体配制品
CN114007641A (zh) * 2019-05-16 2022-02-01 阿斯利康(瑞典)有限公司 使用贝那利珠单抗治疗增强型患者群体慢性阻塞性肺病的方法
CN114423456A (zh) * 2019-09-27 2022-04-29 阿斯利康(瑞典)有限公司 贝那利珠单抗用于治疗迟发性哮喘的方法

Also Published As

Publication number Publication date
HRP20210406T1 (hr) 2021-04-30
ES2866426T3 (es) 2021-10-19
CY1124399T1 (el) 2022-07-22
DK3033104T3 (da) 2019-06-17
EP3033104A2 (en) 2016-06-22
CY1122033T1 (el) 2020-10-14
PL3520811T3 (pl) 2021-08-02
JP6746496B2 (ja) 2020-08-26
LT3520811T (lt) 2021-03-25
JP2016527325A (ja) 2016-09-08
CN111588849A (zh) 2020-08-28
SG11201600483QA (en) 2016-02-26
WO2015023507A3 (en) 2015-04-09
CA2917603A1 (en) 2015-02-19
ES2733602T3 (es) 2019-12-02
PT3520811T (pt) 2021-03-15
EP4579236A3 (en) 2025-09-17
BR112016002317A8 (pt) 2018-06-12
PT3033104T (pt) 2019-06-27
SI3520811T1 (sl) 2021-04-30
US9441046B2 (en) 2016-09-13
RU2016108809A (ru) 2017-09-18
US20150044203A1 (en) 2015-02-12
RS61565B1 (sr) 2021-04-29
EP4579236A2 (en) 2025-07-02
WO2015023507A8 (en) 2015-09-24
WO2015023507A2 (en) 2015-02-19
CA2917603C (en) 2023-05-16
KR20160043049A (ko) 2016-04-20
BR112016002317A2 (pt) 2017-12-12
HK1222559A1 (zh) 2017-07-07
EP3520811B1 (en) 2020-12-30
KR102337599B1 (ko) 2021-12-10
RS58711B1 (sr) 2019-06-28
AU2014306959B2 (en) 2019-11-21
HUE043497T2 (hu) 2019-08-28
RU2016108809A3 (enExample) 2018-06-18
EP3875487A1 (en) 2021-09-08
AU2020201277A1 (en) 2020-03-12
SMT201900311T1 (it) 2019-07-11
RU2703568C2 (ru) 2019-10-21
DK3520811T3 (da) 2021-03-22
JP2020125304A (ja) 2020-08-20
JP7864776B2 (ja) 2026-05-25
EP3033104B1 (en) 2019-04-03
MX2016001384A (es) 2016-08-03
HRP20190920T1 (hr) 2019-07-12
AU2014306959A1 (en) 2016-02-04
MX2021003826A (es) 2021-05-27
EP4636400A2 (en) 2025-10-22
SMT202100152T1 (it) 2021-05-07
PL3033104T3 (pl) 2019-09-30
HUE053627T2 (hu) 2021-07-28
TR201907907T4 (tr) 2019-06-21
EP4636400A3 (en) 2025-12-24
EP3033104A4 (en) 2017-03-22
EP3520811A1 (en) 2019-08-07
MX381102B (es) 2025-03-12
SI3033104T1 (sl) 2019-06-28
HK1225300A1 (en) 2017-09-08
LT3033104T (lt) 2019-06-25
JP2024129140A (ja) 2024-09-26
ME03403B (me) 2020-01-20
JP2022120010A (ja) 2022-08-17

Similar Documents

Publication Publication Date Title
US9441037B2 (en) Methods for reducing exacerbation rates of asthma using benralizumab
US9441046B2 (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
AU2020202564A1 (en) Methods for improving asthma symptoms using benralizumab
HK40129473A (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK40058739A (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK40012636A (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK40012636B (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK40035227A (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK1225300B (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK40035226A (en) Methods for reducing exacerbation rates of asthma using benralizumab

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20170215

Address after: Swedish Sodertalje

Applicant after: AstraZeneca AB

Address before: American Maryland

Applicant before: Medimmune Vaccines Inc.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1222559

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160330

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1222559

Country of ref document: HK